Introduction
The deletion of the long arm of chromosome 6 (6q) is one of the most common chromosome aberrations in a variety of malignant solid tumors (Mertens et al., 1997) , as well as in leukemias, including acute lymphoblastic leukemia, chronic lymphoproliferative disorders and non-Hodgkin's lymphomas (Offit et al., 1993) . Chromosome 6q deletion has also been found in several benign tumors and premalignant diseases, including benign breast fibroadenomas and premalignant breast atypical hyperplasia (Tibiletti et al., 2000) , benign endocrine pancreatic tumors (Barghorn et al., 2001) , benign ovarian cysts (Tibiletti et al., 2001) , thyroid follicular adenomas (Roque et al., 2003) , cervical adenocarcinoma in situ (Acevedo et al., 2002) , breast ductal carcinoma in situ and mammographically detected early invasive carcinomas (Chappell et al., 1997) , early lymphomas (Atkin and Jackson, 1996) and borderline surface epithelial ovarian tumors (Tibiletti et al., 1996) . Chromosome 6q deletion is usually part of the complicated karyotypic abnormalities in these tumors; however, it has been reported as a solitary change (Offit et al., 1994) . Detailed mapping of the 6q deletion performed in several types of tumors indicated at least four common deleted regions at 6q14, 6q21, 6q24 and 6q27 (Qu et al., 1998; Abe et al., 1999; Hu et al., 2001; Jensen et al., 2003) .
The presence of chromosome 6q deletion in a broad range of tumors suggests that chromosome 6q harbors major tumor suppressor gene(s) whose inactivation serves as a common pathologic pathway in these tumors. The observation of 6q deletion in benign tumors and premalignant lesions suggests that the inactivation of the targeted 6q tumor suppressor(s) could be an early event in tumorigenesis. Several functional studies further substantiated the presence of chromosome 6 tumor suppressor gene(s). For example, introduction of a normal human chromosome 6 by microcell-mediated chromosome transfer techniques into several types of tumor cells, including malignant melanoma (Trent et al., 1990; Negrini et al., 1994; Welch et al., 1994) , ovarian cancer (Wan et al., 1999) , breast cancer (Theile et al., 1996) and uterine endometrial carcinoma (Yamada et al., 1990) , resulted in inhibition of tumor cell growth and a reversal of the tumorigenic potential of these cells in nude mice.
We have recently developed a functional screening approach aimed at identifying genes capable of inducing cell transformation. We found that UTRN on 6q24 was capable of inducing cell transformation when expressed in an antisense orientation, suggesting a tumor suppressor role. Further studies showed decreased expression and inactivation mutations of UTRN in tumors. Expression of a wild-type UTRN in breast cancer cells inhibited tumor cell growth in vitro and reduced their tumor potential in nude mice. The tumor suppression mechanism of utrophin could involve its function in maintaining normal cytoskeletal organization and cell membrane integrity.
Results

Functional screening approach for the identification of tumor genes
We designed a functional screening approach to identify genes capable of inducing cell transformation ( Figure 1a) . Genes from primary tumors were expressed in both sense and antisense orientation in non-neoplastic NIH3T3 cells. Cells were cultured in soft-agar plates. Transformed 3T3 cells were identified by their capabilities for anchorage-independent growth. Tumor genes were rescued and sequenced. Genes expressed in sense orientation were considered candidate oncogenes, and those expressed in antisense orientation, which could potentially downregulate the expression of their counterpart in NIH3T3 cells (Biroccio et al., 2003) , were considered candidate tumor suppressor genes. We performed two parallel studies using RNAs from either a mixture of four primary breast cancers or a mixture of three primary prostate cancers. NIH3T3 cells transfected with tumor cDNAs were selected for neomycin resistance for 3 weeks. During this period, a few foci of piled-up cells were observed among cells expressing tumor genes but not among control cells expressing vector only. Transfected cells were then seeded in soft-agar culture plates. In 2 weeks, many big colonies were formed from cells transfected with tumor cDNAs but none were formed from control cells. The morphology of the transformed colonies varied, presumably owing to different functions of individual genes expressed in those colonies (Supplementary Figure 1 ). Fifty-six colonies from cells expressing breast cancer cDNAs and 64 colonies from cells expressing prostate cancer cDNAs were selected under a phase microscope. Colonies were disaggregated with trypsin and expanded in liquid culture. Cells were harvested and tumor genes were rescued by polymerase chain reaction (PCR) with adaptor primers. Most of the colonies contained one tumor gene or one tumor gene fragment. A total of 10 genes, including three genes in sense orientation and seven genes in antisense orientation, were discovered. Two known tumor suppressor genes, TSG101 (Li and Cohen, 1996) and MM-1 (encoding a negative regulator for c-myc) (Fujioka et al., 2001) , were among the seven genes identified in antisense orientation. Other candidate tumor suppressor genes included UTRN, a ribosomal Decreased UTRN expression at 25% or more in tumors (assuming tumor samples containing at least 50% tumor cells with one UTRN inactivated) was observed in five of 10 breast cancers, one of 10 ovary cancers, three of 10 colon cancers, five of 10 stomach cancers, nine of 10 lung cancers, seven of 10 kidney cancers, two of five bladder cancers, two of three trachea cancers, four of five vulvar cancers, two of three liver cancers, zero of four prostate cancers, four of 10 uterine cancers, six of 10 cervical cancers, five of 10 rectal cancers, six of 10 thyroid cancers, five of 10 testis cancers, six of 10 skin cancers, three of seven small intestine cancers and three Table 1 ). In total, 78 of 154 (50.6%) primary tumors showed decreased UTRN expression. We also studied the expression of two immediateneighbor genes of UTRN, STX11 (syntaxin 11; centromeric to UTRN) and EPM2A (epilepsy progressive myoclonus type 2A; telomeric to UTRN). Decreased expression of STX11 and EPM2A was also observed in some tumors (Figure 2c and d), which is consistent with the high frequency of chromosome 6q deletion in tumors. Generally, however, the decreased expression of UTRN in tumors was more dramatic than that of STX11 and EPM2A. We suspect that some tumors have loss of heterozygosity (LOH) in this region, leading to the underexpression of STX11 and EPM2A. In addition to the LOH, UTRN may be hit by other aberrations such as mutations, as described below, which could further decrease the UTRN expression. These data are generally consistent with UTRNs being the target of chromosome 6q aberration.
UTRN downregulation in tumors was also studied by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) in 10 primary breast cancers using cDNAs normalized against a housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Four of 10 breast cancers showed no or significantly decreased UTRN compared to normal breast tissue, and this finding was verified with a second pair of primers located in a separate region of UTRN ( Figure 3a ). Our findings of UTRN downregulation in tumors was consistent with the results obtained in independent studies using gene expression arrays. A search of the public Oncomine expression database (Rhodes et al., 2004) revealed that UTRN has been shown to be significantly decreased in a large variety of primary tumors including lung cancer, breast cancer, colon cancer, seminoma, squamous cell carcinoma of the tongue, glioblastoma, astrocytoma and glioma (Pp0.001). In prostate cancer and glioma, downregulation of UTRN was associated with tumor progression (Pp0.001). In an expression profiling of normal myometrium vs uterine leiomyomas, UTRN was significantly decreased in all five uterine leiomyomas Figure 3 UTRN downregulation in breast cancers and leiomyomas. (a) Semiquantitative RT-PCR was performed to amplify UTRN in 10 primary breast cancers using cDNAs normalized against a housekeeping gene GAPDH. Four of 10 breast cancers (Cases no. 3, 5, 6 and 7) showed no or significantly decreased UTRN compared to normal breast tissue. (b) Gene expression arrays showed that UTRN expression was significantly decreased in primary leiomyomas. The log 2 values of the original signals were used in t-test, yielding a P-value of 0.00039. The 95% confidence interval of UTRN in normal samples was 7.57-7.87. All five leiomyomas showed decreased UTRN expression outside this range. The UTRN neighbor genes EPM2A (telomeric) and PLAGL1 (centromeric) did not differ significantly between normal myometrium and uterine leiomyomas (see Supplementary  Figure 2 ).
UTRN mutation in multiple tumors Y Li et al (Po0.001) (Affymetrix Human Genome U133A Array; probe set 213022_s_at; GEO data set ID GDS484; Figure 3b ). In contrast, the UTRN neighbor genes EPM2A (telomeric) and PLAGL1 (centromeric) did not differ significantly between normal myometrium and uterine leiomyomas (Supplementary Figure 2) . Another UTRN neighbor gene STX11 was not detected in either normal myometrium or uterine leiomyomas (Hoffman et al., 2004) .
UTRN mutations in tumors UTRN is a large gene with 74 exons spanning B900 kb at chromosome 6q24. To study potential UTRN mutations, we performed RT-PCR coupled with a protein truncation test (PTT). The entire 10302 bp UTRN coding sequence was initially amplified with two overlapped PCR reactions. The PCR products were then re-amplified with five pairs of nested primers with a T7 promoter sequence incorporated in forward primers. All the PCR products were subjected to in vitro transcription and translation studies. Those PCR products showing aberrant-sized proteins in the PTT assay were purified and sequenced. In 62 primary breast cancers, 21 mutations were detected in 18 cases (29%), including three cases with two mutations each. In 20 primary neuroblastomas, five mutations were found in four cases (20%), including one case with two mutations. In 15 primary malignant melanomas, four mutations were found in four cases (27%) ( Table 2) . Most of the mutations were deletions involving one or more exons that led to the truncation of utrophin. One breast cancer (case B23) contained a nonsense mutation (8080A>T) (Figure 4a ). Two breast cancers (cases B11 and B24) had splicing errors: case B11 had an enlarged exon 63 with 611 bp intronic sequence included at the 3 0 end, resulting from the use of a cryptic donor site in intron 64. A point mutation in the proximity of the normal exon 63 donor site (9245 þ 20G>A) was found. Case B24 contained a 'new' exon of 124 bp sequence from intron 65. No mutations were noted in the proximity of splice donor/acceptor sites for exon 64, 65 and the 'new' exon. The splicing errors from both cases resulted in a reading frame shift (Figure 4b and c).
Inhibition of tumor cell growth by overexpressing utrophin
To study the tumor suppression function of utrophin, breast cancer cell lines HTB20 and CRL1500 (ATCC) were transfected with a G-UTRN/green fluorescent Figure 4 PTT analysis of three breast cancers with UTRN mutations. Case B23 had a nonsense mutation (a); case B11 (b) and case B24 (c) had splicing errors that generated a premature stop codon. Arrows indicate the full-length PTT products.
UTRN mutation in multiple tumors Y Li et al protein (GFP) construct that encodes an utrophin isoform G-utrophin (Blake et al., 1995) . As controls, cells were also transfected with an empty GFP vector and a human UTRN mutant/GFP construct expressing a mutant UTRN with a deletion of exon 10, which was found in multiple primary tumors (see Table 1 ) and led to a premature stop codon at position 391. Three days after transfection, most tumor cells expressing G-UTRN/GFP were replaced by GFP-negative cells (presumably non-transfected cells or cells expressing lower levels of G-UTRN/GFP), in the absence of selection, suggesting that growth of tumor cells overexpressing G-utrophin/GFP is not favored in this assay.
No such 'selection' against tumor cells expressing only GFP or the human UTRN mutant/GFP construct was detected (Figure 5a ). In another set of experiments, forced expression of G-UTRN/GFP in tumor cells was achieved by selection for 3 weeks in medium containing neomycin. Cells were then cultured in soft agar plates (10 3 cells/35 mm plate) for 3 weeks. Tumor cells expressing G-UTRN/GFP formed significantly smaller and fewer colonies than those expressing the UTRN mutant/ GFP or only GFP (Figure 5b) . Interestingly, expression of G-UTRN/GFP in breast cancer cell line CRL 1500 induced morphological changes in cultured cells. CRL 1500 cells typically grow as isolated clumps. Islands of single-layered cells, morphologically typical of epithelial cells, start to appear in CRL 1500 cells expressing G-UTRN/GFP 3 weeks after transfection (Figure 5c ). No such morphologic changes were observed in CRL 1500 cells expressing UTRN mutant/GFP or only GFP. Potential cell contamination from other sources was excluded by performing a fluorescence in situ hybridization analysis on cells grown in chamber slides with a panel of probes for chromosomes 8, 9, 18 and X, which showed an identical signal pattern between the single layer of epithelial cells and the CRL 1500 disaggregated cell clumps (Supplementary Figure 3) . Tumorigenesis of G-UTRN-transfected or UTRN mutant-transfected breast cancer HTB20 cells in athymic CD-1 nude mice was studied by injecting 2 Â 10 7 tumor cells subcutaneously on both sides of the flanks. Ten sites on five mice were injected for each group of cells. After 42 days, two of 10 sites injected with G-UTRN-transfected breast cancer cells developed tumors, whereas eight of 10 sites injected with UTRN mutant-transfected breast cancer cells developed tumors.
Discussion
The deletion of chromosome 6q has been extensively mapped in a variety of tumors. Several studies showed a minimal deletion region of 6q in a 12.5 Mb region on 6q24 flanked by D6S311 and D6S292 (Noviello et al., 1996; Huang et al., 2000; Hu et al., 2001) . UTRN is located in this region, with 3.5 Mb centromeric to D6S311 and 8 Mb telomeric to D6S292. One study used UTRN as one of the polymorphic markers and concluded that UTRN was the most commonly deleted locus in pancreatic carcinoma (Barghorn et al., 2001) . The presence of a tumor suppressor gene in this commonly deleted region was further confirmed by a functional study on breast cancer cells/exogenous chromosome 6 hybrid, in which all seven hybrid clones that had lost their malignant phenotype contained the same 12.5 Mb region at 6q24 from the exogenous chromosome 6 (Theile et al., 1996) .
UTRN is a family member of DMD gene, which encodes dystrophin. Inactivation of dystrophin causes Duchenne/Becker muscular dystrophy, a lethal childhood disease characterized by rapid progression of muscle degeneration and enlargement of muscles. UTRN mutation in multiple tumors Y Li et al UTRN shares similarity with DMD at both the nucleic acid (65%) level and the amino-acid level (80%). DMD is most abundant in skeletal and cardiac muscle, whereas UTRN is expressed ubiquitously (Schofield et al., 1993) . The introns of both genes contain a high percentage of repeat sequences, with 28.4% for UTRN and 32.1% for DMD (Pozzoli et al., 2002) . The intronic repeat sequences were suspected causes of aberrant recombinations that led to the intragenic deletions of the DMD gene, which is one of the most mutable genes in human genome, with a calculated mutation rate of 1 in 10 000 (Moser, 1984) . In this study, we observed UTRN mutations in multiple tumors. Similar to DMD, most of the UTRN mutation comprised intragenic deletions.
Our detection of UTRN inactivation mutations in tumors, the induction of cellular transformation by the expression of UTRN antisense, and the inhibition of tumor cell growth by the expression of UTRN are consistent with a tumor suppressor role for utrophin. It is puzzling how a dystrophin-related protein could function as a tumor suppressor. Both utrophin and dystrophin contain an actin-binding N-terminal domain, a triple coiled-coil repeat central region, and a Cterminal domain that consists of protein-protein interaction motifs, which interact with the transmembrane dystroglycan protein components. Both utrophin and dystrophin play roles in the maintenance of cell membrane integrity by linking the actin cytoskeleton to the extracellular matrix (Pearce et al., 1993; Deconinck et al., 1997) . A precedent for a tumor suppressor participating in the maintenance of cell membrane integrity is the neurofibromatosis 2 (NF2) tumor suppressor merlin. Merlin contains an N-terminal domain that binds to both transmembrane proteins and actin, linking the actin cytoskeleton to the extracellular matrix (Brault et al., 2001) . By maintaining normal cytoskeletal organization and cell membrane integrity, merlin functions as a positive growth regulator (Gutmann et al., 1999) . Similar pathways could also be involved in the tumor suppression function of utrophin, which unlike merlin is widely expressed in various cell types. The exact mechanisms by which utrophin participates in cell proliferation and transformation, however, warrant further studies.
Materials and methods
Functional screening of transforming genes
Total RNAs from four breast cancers and three prostate cancers were isolated with TriPure Isolation Reagents (Invitrogen, Carlsbad, CA, USA). mRNAs were isolated with a Oligotex mRNA mini-kit (Qiagen, Valencia, CA, USA). cDNAs were synthesized with a SMART PCR cDNA synthesis kit (Clontech). For first-strand cDNA synthesis, 1 mg of mRNA was reverse transcribed with a PowerScript reverse transcriptase, an oligo d(T) 3 0 -adaptor primer, and a SMART II A oligonucleotide containing a terminal stretch of G residues that serve as an extended template for reverse transcription (5 0 -adaptor). First-strand cDNAs were amplified with 10 cycles of PCR using the adaptor primers. PCR products were TA cloned into pcDNA3.1/V5-His TOPO expression vector (Invitrogen). Plasmid DNA was transfected into NIH 3T3 cells with Lipofectamine 2000 reagents (Invitrogen). Cells were selected in the presence of neomycin (400 mg/ml) for 3 weeks before proceeding to a soft-agar assay. Transfected cells (2 Â 10 5 ) were suspended in 15 ml of soft agar equilibrated at 401C (0.35% Bactoagar in RPMI 1640 with 10% fetal calf serum (FCS)), plated on 20 ml of solidified agar (0.5% Bactoagar in RPMI 1640 with 10% FCS) in a P-150 culture dish. Six P-150 soft-agar plates, including three for breast cancer cDNAs and three for prostate cancer cDNAs, were used for this study. Soft-agar plates were cultured at 371C in 5% CO 2 for 2-3 weeks. For the negative control, NIH3T3 cells were transfected with empty vector, selected in the presence of neomycin and seeded in a P-35 soft-agar plate. Transformed colonies were picked up under a phase microscope with 1000 ml pipette tips with their tips cutoff. Colonies were disaggregated with trypsin and expanded in liquid culture. Cells were harvested and DNAs were isolated. Tumor genes were rescued by PCR with adaptor primers (from the SMART PCR cDNA synthesis kit). PCR products were sequenced with a primer derived from the 5 0 -adaptor sequence (5 0 -CGCAGAGTACGCGGG-3 0 ). The expression orientation of each candidate cancer gene was determined by PCR with a forward primer derived from a vector sequence upstream of the cloning site (T7 promoter primer) and one of the two genespecific reverse primers: one complementary to the sense strand of the gene and the other complementary to the antisense strand of the gene.
Northern blot analysis of cancer profiling array
The Cancer Profiling Array II (Clontech) was hybridized with a 2.6-kb 3 0 -end cDNA fragment of UTRN (PTT5; see below in PTT of UTRN) in the ExpressHyb Hybridization Solution (Clontech) at 681C overnight. The blot was washed in 0.1X-2X SSC/SDS solutions and exposed to X-ray film at À801C for 1-3 days. The same blot was also hybridized with full-length cDNA probes for STX11 and EPM2A, as well as with the loading control probe for human ubiquitin cDNA. After each hybridization, the probe was stripped by placing the blot in boiling 0.5% SDS solution.
Semiquantitative RT-PCR amplification of UTRN Total RNA from frozen tumor samples was isolated with TriPure Isolation Reagents. Two microgram of total RNA was used for reverse transcription in a 20-ml reaction using random 9-mers primers (RNA PCR kit; TaKaRa). One microliter of cDNA was used to amplify GAPDH as an interior control (F/ GAPDH/110: 5 0 -aggtgaaggtcggagtcaac-3 0 ; R/GAPDH/610: 5 0 -catccatgacaactttggta-3 0 ). PCR conditions were 951C 30 s, 551C 40 s; 721C 50 s for 27 cycles using rTaq polymerase (TaKaRa). UTRN was amplified with 1 ml cDNA using two pairs of primers located in separate regions of UTRN (F/UTRN/11: 5 0 -atggagaacatgaagccagtcc-3 0 and R/UTRN/2257: 5 0 -ccatttgc tccacaaggatttg-3 0 ; F/UTRN/1900: 5 0 -caggtgactcaggctgtagcaa ag-3 0 and R/UTRN/4048: 5 0 -gcaagacttgaagcatctggtcag-3 0 ). PCR conditions were: 951C 50 s, 621C 50 s; 721C 2 min for 30 cycles using LA Taq polymerase (TaKaRa). PCR products were visualized in 0.8% agarose gel. 0 and R/UTRN/PTT5: 5 0 -cctagtgaatctgctccatgacctc-3 0 ). All nested PCR was performed with rTag polymerase under the following conditions: 941C 30 s, 601C 30 s; 721C 3 min for 35 cycles. PCR products were visualized in 0.8% agarose gel and used directly for in vitro TNT analysis using the TNT Quick Coupled Transcription/ Translation System (Promega) according to the manufacturer's instructions. In brief, 0.5 ml of PCR product was incubated with 2.5 ml of TNT T7 Quick Master Mix and 0.125 ml of [ 35 S]methionine at 301C for 60 min. TNT products were separated in 4-20% polyacrylamide gel, fixed, visualized by incubating with fluorography Amplify solution (Amersham, Piscataway, NJ, USA) and exposed to X-ray films overnight at room temperature. PCR products showing aberrant-sized proteins in PTT assay were purified and sequenced. All the sequence variations were confirmed by performing a separate cDNA synthesis, RT-PCR, and sequencing analysis.
Protein truncation test
UTRN expression constructs cDNA encoding a mouse utrophin isoform (G-utrophin) was amplified with a forward primer with BglII site incorporated (F/G-UTRN/BglII: 5 0 -attagatctatgcaaattctgaggactcttcagaag-3 0 ) and a reverse primer with HindIII site incorporated (R/ G-UTRN/HindIII: 5 0 -cgaagcttgtcacattgcctgtggcctgctgg-3 0 ). PCR product was digested and ligated into BglII and HindIII sites of PEGFP-C1 (Clontech), to fuse with GFP. For a UTRN mutant construct, cDNA from a breast cancer specimen known to harbor an exon 10 deletion was amplified with a forward primer with XhoI site incorporated (F/UTRN E10D/ XhoI: 5 0 -aatctcgagctatggccaagtatggagaacatgaagccag-3 0 ) and a reverse primer with KpnI site incorporated (R/UTRN E10D/ KpnI: 5 0 -taaggtaccctaggatagctgtagcgctctcaccac-3 0 ). PCR product was digested and ligated into XhoI and KpnI sites of PEGFP-C1. For an antisense UTRN construct, UTRN was amplified with a forward primer with EcoRI site incorporated (F/UTRN/10451/EcoRI: 5 0 -ctcgaattcgacccattcaaccccaaagctcc gtg-3 0 ) and a reverse primer with a BamHI site incorporated (R/UTRN/12381/BamHI: 5 0 -cacggatccgtgttaaaattacttttattcaggatga-3 0 ). PCR product was digested and ligated into BamHI and EcoRI sites of pcDNA3.1 (Invitrogen). All the constructs were transfected into cells with Lipofectamine 2000.
Experimental mouse tumor studies
All mouse experiments were approved and monitored by The Center for Animal Resources and Comparative Medicine at Harvard Medical School. Athymic mice were kept in specificpathogen-free facilities. To grow xenographic mouse tumors, 2 Â 10 7 breast cancer HTB20 cells expressing a wild-type Gutrophin or an utrophin mutant were injected subcutaneously into both sides of the flanks of 5-week-old nude mice (Charles River Laboratories, Inc., Wilmington, MA, USA) Mice were monitored daily for 6 weeks. At the end of the experiment, mice were euthanized by CO 2 inhalation.
